[go: up one dir, main page]

SI2354161T1 - Anti-nr10 antibody, and use thereof - Google Patents

Anti-nr10 antibody, and use thereof

Info

Publication number
SI2354161T1
SI2354161T1 SI200931302T SI200931302T SI2354161T1 SI 2354161 T1 SI2354161 T1 SI 2354161T1 SI 200931302 T SI200931302 T SI 200931302T SI 200931302 T SI200931302 T SI 200931302T SI 2354161 T1 SI2354161 T1 SI 2354161T1
Authority
SI
Slovenia
Prior art keywords
antibody
Prior art date
Application number
SI200931302T
Other languages
Slovenian (sl)
Inventor
Taichi Kuramochi
Keiko Kasutani
Souhei Ohyama
Hiroyuki Tsunoda
Tomoyuki Igawa
Tatsuhiko Tachibana
Hirotake Shiraiwa
Keiko Esaki
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2008/072152 external-priority patent/WO2009072604A1/en
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority claimed from EP09830463.7A external-priority patent/EP2354161B1/en
Publication of SI2354161T1 publication Critical patent/SI2354161T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931302T 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof SI2354161T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2008/072152 WO2009072604A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
PCT/JP2009/054941 WO2010064456A1 (en) 2008-12-05 2009-03-13 Anti-nr10 antibodies and utilization of the same
EP09830463.7A EP2354161B1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
PCT/JP2009/070376 WO2010064697A1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof

Publications (1)

Publication Number Publication Date
SI2354161T1 true SI2354161T1 (en) 2015-12-31

Family

ID=42234508

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931302T SI2354161T1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof

Country Status (5)

Country Link
KR (1) KR20160062207A (en)
MY (1) MY154715A (en)
SI (1) SI2354161T1 (en)
TW (1) TWI432209B (en)
WO (1) WO2010064456A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
RU2526512C2 (en) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Modified constant region of antibody
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Antibody constant region variant
WO2014208645A1 (en) * 2013-06-28 2014-12-31 中外製薬株式会社 Method for predicting response of patient with pruiritic disease to il-31 antagonist therapy
TW202515609A (en) * 2015-04-14 2025-04-16 日商中外製藥股份有限公司 Pharmaceutical composition for the prevention and/or treatment of atopic dermatitis containing an IL-31 antagonist as an active ingredient
KR102886159B1 (en) 2015-04-14 2025-11-13 추가이 세이야쿠 가부시키가이샤 Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
MX2022005654A (en) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING ANTIBODY.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL309249A1 (en) * 1992-12-01 1995-10-02 Protein Design Labs Humanised antibodies against l-selectin
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JP3946256B2 (en) * 1995-09-11 2007-07-18 協和醗酵工業株式会社 Antibody to human interleukin 5 receptor α chain
EP2325316B8 (en) * 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
AU2004229311B2 (en) * 2003-03-04 2009-07-09 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
MX2007007935A (en) * 2004-12-28 2007-12-06 Innate Pharma Sa Monoclonal antibodies against nkg2a.
AU2006214404B2 (en) * 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
UY29504A1 (en) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PT2047863E (en) * 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
WO2007147122A2 (en) * 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
DE602008004296D1 (en) * 2007-02-14 2011-02-17 Vaccinex Inc HUMANIZED ANTI-CD100 ANTIBODIES
SI2426144T1 (en) * 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
AU2008304756B8 (en) * 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
CN101874042B9 (en) * 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR

Also Published As

Publication number Publication date
MY154715A (en) 2015-07-10
KR20160062207A (en) 2016-06-01
WO2010064456A1 (en) 2010-06-10
TW201028165A (en) 2010-08-01
TWI432209B (en) 2014-04-01

Similar Documents

Publication Publication Date Title
PL2354161T3 (en) Anti-nr10 antibody, and use thereof
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) P95-her2 antibodies and uses thereof
LT2436696T (en) Anti-beta-amyloid antibody and uses thereof
IL241091B (en) Antibodies against fcrn and use thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
ZA201003025B (en) Anti-hepcidin antibodies and uses thereof
EP2334330A4 (en) Anti-cd147 antibodies, methods, and uses
ZA201100261B (en) Anti-hepcidin-25 selective antibodies and uses thereof
IL210804A (en) Benzylidenehydrazides and uses thereof
EP2241578A4 (en) Anti-cldn6 antibody
EP2307344A4 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
IL236237A (en) Tmem154 antibodies and fragments and uses thereof
GB0807018D0 (en) Antibodies and treatment
EP2291377A4 (en) Imidazopyrimidinones and uses thereof
SI2354161T1 (en) Anti-nr10 antibody, and use thereof
ZA201103456B (en) Leukolectins and uses thereof
PL2247601T3 (en) Thiazopyrimidinones and uses thereof
IL209718A0 (en) Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof
GB0703763D0 (en) Bone-replacement materials,methods and devices
SI2376479T1 (en) Substituted furancarboxamides, and use thereof
ZA201101547B (en) Anti-extended type i glycosphingolipid antibody,derivatives thereof and use
GB0812277D0 (en) Antibody and uses thereof
GB0911770D0 (en) Antibody
GB0906115D0 (en) Antibody and uses thereof